Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 7/20 | 0.41 |
| ▸ | MMP2 | P08253 | 6/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25747757 | 0.84 | MMP2 (0.41) | HRH3MMP3MMP2MMP1MMP9 | |
| SCHEMBL25040870 | 0.84 | MMP2 (0.41) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL25040866 | 0.84 | MMP2 (0.41) | HRH3MMP3MMP2MMP1MMP9 | |
| SCHEMBL25747837 | 0.82 | ALDH1A1 (0.38) | HRH3 | |
| SCHEMBL7228479 | 0.81 | HRH3 (0.56) | HRH3KIF11MMP3MMP2MMP1 | |
| SCHEMBL25040490 | 0.80 | HRH3 (0.50) | HRH3KIF11MMP3MMP2MMP1 | |
| SCHEMBL25040918 | 0.78 | ERN1 (0.47) | — | |
| SCHEMBL9062436 | 0.77 | HRH3 (0.55) | HRH3KIF11HDAC1HDAC2 | |
| SCHEMBL25040868 | 0.75 | BCHE (0.40) | MMP3MMP2 | |
| SCHEMBL9195885 | 0.73 | MAOB (0.56) | HRH3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-07-04 | — | — | US | disclosed |
| US-20230051259-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051259-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885KIF11 2738/4885MMP3 4655/4885 |
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885KIF11 2738/4885MMP3 4655/4885 |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885KIF11 2738/4885MMP3 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.